Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
From outside firms

Analysis and Perspectives

Commentary and analysis from outside consulting and policy firms. Not part of Medicaid Monitor's independently scored news coverage. Each piece links back to the firm's original publication.

Avalere · Feb 20

How Generic Drug Manufacturers Face Medicaid Inflation Penalties Without Actually Raising Prices

This white paper examines how the Medicaid Drug Rebate Program's inflation penalty can trigger rebate obligations for generic manufacturers even when they haven't increased prices beyond inflation, due to purchasing pattern shifts, seasonal fluctuations, or commodity market dynamics. The analysis details five scenarios where AMP increases occur mechanically rather than through deliberate price hikes, creating financial pressure on generics manufacturers operating on thin margins. For MCO pharmacy programs and state Medicaid finance teams, this explains important dynamics affecting generic drug availability and rebate calculations.

Read at advisory.avalerehealth.com →
Avalere · Feb 12

340B Program Cost States $2 Billion in Foregone Medicaid Rebates in 2023, Analysis Finds

When 340B covered entities shift hospital outpatient drug claims from Medicaid into the 340B program, state Medicaid programs lose access to manufacturer rebates—totaling an estimated $2 billion in 2023 alone. The analysis highlights how rapid 340B growth, particularly among rural referral centers and disproportionate share hospitals, creates budget pressure for state Medicaid programs while patients may not receive direct cost-sharing relief. This matters for MCO compliance and finance teams navigating drug pricing arrangements and state directors managing pharmacy budgets under constrained fiscal conditions.

advisory.avalerehealth.com →
Avalere · Jan 28

Health Plans Face Strategic Choices on Enterprise Data Integration by 2030

Avalere and Tenasol argue that health plans currently operate fragmented data systems that create technical debt and compliance risks while missing opportunities for quality improvement. The analysis projects that plans will need enterprise-level data strategies integrating expanded sources—including social determinants of health data and electronic medical records—with emerging technologies to drive operational efficiency. While the piece addresses all health plans generically, Medicaid managed care organizations face particular pressure to integrate SDOH data and demonstrate quality outcomes under state contracts.

advisory.avalerehealth.com →
Avalere · Jan 28

Federal Vaccine Advisory Committee Delays Could Impact State Medicaid Coverage Decisions

The Trump administration's temporary communications pause has postponed key vaccine advisory committee meetings that typically inform coverage policies across federal and state health programs. The piece examines how delays in vaccine recommendations from CDC and HHS committees could create downstream challenges for public health implementation, though it does not specifically address Medicaid managed care operations or state program implications. The analysis focuses primarily on federal vaccine policy infrastructure and advisory processes rather than payer-specific concerns.

advisory.avalerehealth.com →
Avalere · Jan 17

IRA Drug Price Negotiation Expands to 15 More Products, Including High-Spend Diabetes and Behavioral Health Drugs

CMS has selected 15 additional Part D drugs for Medicare price negotiation under the Inflation Reduction Act, representing $41 billion in Part D spending and affecting 5.3 million beneficiaries. The list includes high-cost medications for diabetes, behavioral health conditions, and cancer that are also commonly covered in Medicaid managed care formularies. While the negotiation applies to Medicare, the pricing pressure and manufacturer strategies could influence Medicaid rebate structures and drug access in managed care plans that cover dual-eligible populations.

advisory.avalerehealth.com →

Get the daily briefing.